Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F, Labianca R, Zaniboni A, Lonardi S, Galli F, Rulli E, Rosati G, Corallo S, Ronzoni M, Cardellino GG, Mattioli R, Mambrini A, Ciuffreda L, Banzi M, Pusceddu V, Maiello E, Zampino M, Zagonel V, Marchetti P, Corsi D, Rimassa L, Cinieri S, Sobrero A. Petrelli F, et al. Among authors: mattioli r. JAMA Oncol. 2020 Apr 1;6(4):547-551. doi: 10.1001/jamaoncol.2019.6486. JAMA Oncol. 2020. PMID: 32053133 Free PMC article. Clinical Trial.
Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis.
Rosati G, Galli F, Cantore M, Bergamo F, Banzi M, Zampino MG, Mattioli R, Cardellino GG, Ronzoni M, Di Bartolomeo M, Tamberi S, Marchetti P, Rimassa L, Corsi D, Bochicchio AM, Artioli F, Labianca R, Galli F, Rulli E, Bilancia D, Bregni G; TOSCA (Three or Six Colon Adjuvant) Investigators. Rosati G, et al. Among authors: mattioli r. Oncologist. 2020 Jun;25(6):e928-e935. doi: 10.1634/theoncologist.2019-0736. Epub 2020 Jan 13. Oncologist. 2020. PMID: 31943506 Free PMC article. Clinical Trial.
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial.
Rosati G, Lonardi S, Galli F, Di Bartolomeo M, Ronzoni M, Zampino MG, Banzi M, Zaniboni A, Pasini F, Bozzarelli S, Garattini SK, Ferrari D, Montesarchio V, Mambrini A, Ciuffreda L, Galli F, Pusceddu V, Carlomagno C, Bidoli P, Amoroso D, Bochicchio AM, Frassineti L, Corsi D, Bilancia D, Pastorino A, De Stefano A, Labianca R; TOSCA (Three or Six Colon Adjuvant) investigators. Rosati G, et al. Eur J Cancer. 2021 May;148:190-201. doi: 10.1016/j.ejca.2021.01.051. Epub 2021 Mar 18. Eur J Cancer. 2021. PMID: 33744715
Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Colucci G, Giuliani F, Garufi C, Mattioli R, Manzione L, Russo A, Lopez M, Parrella P, Tommasi S, Copetti M, Daniele B, Pisconti S, Tuveri G, Silvestris N, Maiello E. Colucci G, et al. Among authors: mattioli r. Oncology. 2010;79(5-6):415-22. doi: 10.1159/000323279. Epub 2011 Apr 7. Oncology. 2010. PMID: 21474966 Clinical Trial.
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.
Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R, Genestreti G, Boni C, Ciuffreda L, Di Costanzo F, de Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C, Mattioli R, Cafferata MA, Camisa R, Smit EF. Ardizzoni A, et al. Among authors: mattioli r. J Clin Oncol. 2012 Dec 20;30(36):4501-7. doi: 10.1200/JCO.2012.43.6758. Epub 2012 Oct 29. J Clin Oncol. 2012. PMID: 23109689 Clinical Trial.
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients.
Catalano V, Bergamo F, Cremolini C, Vincenzi B, Negri F, Giordani P, Alessandroni P, Intini R, Stragliotto S, Rossini D, Borelli B, Santini D, Sarti D, Rocchi MBL, Lonardi S, Falcone A, Zagonel V, Mattioli R, Graziano F. Catalano V, et al. Among authors: mattioli r. J Cancer Res Clin Oncol. 2020 Feb;146(2):493-501. doi: 10.1007/s00432-019-03077-w. Epub 2019 Nov 6. J Cancer Res Clin Oncol. 2020. PMID: 31691872
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer.
Cascinu S, Silva RR, Labianca R, Barni S, Mattioli R, Martignoni G, Frontini L, Gasparini G, Catalano V, Baldelli AM, Giuliodori L, Agostinelli R, Catalano G. Cascinu S, et al. Among authors: mattioli r. Ann Oncol. 1999 Aug;10(8):985-7. doi: 10.1023/a:1008373817826. Ann Oncol. 1999. PMID: 10509163 Free article. Clinical Trial.
Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.
Bracarda S, Gernone A, Gasparro D, Marchetti P, Ronzoni M, Bortolus R, Fratino L, Basso U, Mazzanti R, Messina C, Tucci M, Boccardo F, Cartenì G, Pinto C, Fornarini G, Mattioli R, Procopio G, Chiuri V, Scotto T, Dondi D, Di Lorenzo G. Bracarda S, et al. Among authors: mattioli r. Future Oncol. 2014 May;10(6):975-83. doi: 10.2217/fon.13.256. Epub 2013 Dec 3. Future Oncol. 2014. PMID: 24295376 Clinical Trial.
Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer.
Veccia A, Caffo O, De Giorgi U, Di Lorenzo G, Ortega C, Scognamiglio F, Aieta M, Facchini G, Mansueto G, Mattioli R, Procopio G, Zagonel V, D'Angelo A, Spizzo G, Bortolus R, Donini M, Lo Re G, Massari F, Vicario G, Zucali PA, Alesini D, Bonetti A, Mucciarini C, Nicodemo M, Berruti A, Fratino L, Lodde M, Messina C, Perin A, Santini D, Sava T, Tucci M, Basso U, Maines F, Burgio LS, Galligioni E. Veccia A, et al. Among authors: mattioli r. Future Oncol. 2016 Feb;12(4):493-502. doi: 10.2217/fon.15.302. Epub 2016 Jan 18. Future Oncol. 2016. PMID: 26776493
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M. Ruzzo A, et al. Among authors: mattioli r. J Clin Oncol. 2007 Apr 1;25(10):1247-54. doi: 10.1200/JCO.2006.08.1844. J Clin Oncol. 2007. PMID: 17401013
253 results